Related Experiment Video
Updated: Aug 5, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA
Shixian Liu1, Kaixuan Wang2, Hao Chen3
1Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China; NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, 250012, China; Center for Health Management and Policy Research, Shandong University, Shandong Provincial Key New Think Tank, Jinan, 250012, China; Center for Health Preference Research, Shandong University, Jinan, 250012, China.
Purpose:
Inavolisib plus palbociclib and fulvestrant has been approved for treating PIK3CA-mutated, hormone receptor-positive human epidermal growth factor receptor 2-negative (HR + HER2-), advanced breast cancer in the USA. This study evaluated the cost-effectiveness of inavolisib plus palbociclib and fulvestrant compared with palbociclib plus fulvestrant from the US payer perspective.
Methods:
We developed a partitioned survival model at a 28-day cycle length over 15-year time horizons to predict total costs, life-years, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), and incremental cost-utility ratio (ICUR) at willingness-to-pay (WTP) threshold of $150,000 per QALY. Survival data were extracted from the INAVO120 clinical trial, costs and utilities were obtained from the department of Veterans Affairs, published literature and quality-of-life studies using the EQ-5D-5L scale. Uncertainty was addressed via scenario, one-way and probabilistic sensitivity analyses.
Results:
In the base-case, inavolisib plus palbociclib and fulvestrant resulted in 1.99 life-years and 1.43 QALYs at an incremental cost of $211,639.64 with an ICER of $106,595.61 per life-year and an ICUR of $148,417.37 per QALY. The utility value of progression-free survival was the most influential parameter on the base-case results. Alterations in each model parameter did not significantly impact on the conclusions. The probability of inavolisib plus palbociclib and fulvestrant was cost-effective at the WTP threshold of $150,000 was 54.59%.
Conclusion:
Inavolisib plus palbociclib and fulvestrant may be a high-value treatment option for patients with PIK3CA-mutated, HR + HER2-, advanced breast cancer in the USA.
